Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook [Yahoo! Finance]
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference